Accelerating Bionano’s OGM Adoption Hands-
Post# of 84
(Total Views: 54)
Posted On: 07/31/2025 5:11:11 PM
Accelerating Bionano’s OGM Adoption
Hands-on training, combined with emerging guidelines and policy support, has rapidly lowered barriers for OGM implementation in European hospital and research labs.
Early 2025 saw EU health policy reforms introduce reimbursement pathways for advanced genomic diagnostics, encouraging hospital labs to adopt OGM for cancer and rare disease testing.
Strategic collaborations begun in Q1 2025 between OGM providers and leading academic centers, such as the Max Planck Institute, have generated clinical validation data in lymphoma and leukemia applications, fueling confidence among clinical lab directors.
More than a dozen European clinical laboratories, spanning Germany, France, Italy, and the UK, have already initiated pilot OGM workflows following workshop attendance and are engaging Bionano for on-site VIA™ integration support.
Requests for advanced masterclasses on custom pipeline development and cloud-based VIA™ deployment surged by over 60% in the month after the workshops, signaling strong demand for deeper technical training and support.
These combined efforts are catalyzing the integration of Bionano Genomics’ OGM into routine diagnostics, with full clinical adoption expected to accelerate throughout 2025 and beyond.
Hands-on training, combined with emerging guidelines and policy support, has rapidly lowered barriers for OGM implementation in European hospital and research labs.
Early 2025 saw EU health policy reforms introduce reimbursement pathways for advanced genomic diagnostics, encouraging hospital labs to adopt OGM for cancer and rare disease testing.
Strategic collaborations begun in Q1 2025 between OGM providers and leading academic centers, such as the Max Planck Institute, have generated clinical validation data in lymphoma and leukemia applications, fueling confidence among clinical lab directors.
More than a dozen European clinical laboratories, spanning Germany, France, Italy, and the UK, have already initiated pilot OGM workflows following workshop attendance and are engaging Bionano for on-site VIA™ integration support.
Requests for advanced masterclasses on custom pipeline development and cloud-based VIA™ deployment surged by over 60% in the month after the workshops, signaling strong demand for deeper technical training and support.
These combined efforts are catalyzing the integration of Bionano Genomics’ OGM into routine diagnostics, with full clinical adoption expected to accelerate throughout 2025 and beyond.
(0)
(0)